Halozyme Therapeutics, Inc. $HALO Stock Position Lowered by Hantz Financial Services Inc.

Hantz Financial Services Inc. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 134,780 shares of the biopharmaceutical company’s stock after selling 17,004 shares during the quarter. Hantz Financial Services Inc. owned about 0.11% of Halozyme Therapeutics worth $7,011,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Isthmus Partners LLC lifted its holdings in shares of Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 169 shares during the period. OneDigital Investment Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 1.7% in the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 175 shares during the period. Xponance Inc. lifted its holdings in shares of Halozyme Therapeutics by 1.1% in the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 198 shares during the period. Bessemer Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 207 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 4.0% in the first quarter. Nisa Investment Advisors LLC now owns 5,611 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 215 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 1.0%

NASDAQ:HALO opened at $64.63 on Friday. The firm has a market capitalization of $7.56 billion, a price-to-earnings ratio of 14.79, a PEG ratio of 0.35 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The business’s fifty day moving average price is $71.30 and its 200 day moving average price is $62.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Nicole Labrosse sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 108,227 shares of company stock valued at $7,779,595. Company insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HALO. Morgan Stanley cut their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. Benchmark boosted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. Finally, Zacks Research lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Four investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $73.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.